The validation cohort differed from the derivation cohort with respect to age, primary health care referral, symptoms, treatment with aspirin, benign anorectal lesions, a positive FIT result (≥20 μg Hb/g of faeces), caecal intubation and CRC prevalence. The gene discussed is GSTM1; the disease is colorectal carcinoma.